HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis

The administration of antiretrovirals before HIV exposure to prevent infection (i.e., preexposure prophylaxis; PrEP) is under evaluation in clinical trials. Because PrEP is based on antiretrovirals, there is considerable concern that it could substantially increase transmitted resistance, particularly in resource-rich countries. Here we use a mathematical model to predict the effect of PrEP interventions on the HIV epidemic in the men-who-have-sex-with-men community in San Francisco. The model is calibrated using Monte Carlo filtering and analyzed by constructing nonlinear response hypersurfaces. We predict PrEP interventions could substantially reduce transmission but significantly increase the proportion of new infections caused by resistant strains. Two mechanisms can cause this increase. If risk compensation occurs, the proportion increases due to increasing transmission of resistant strains and decreasing transmission of wild-type strains. If risk behavior remains stable, the increase occurs because of reduced transmission of resistant strains coupled with an even greater reduction in transmission of wild-type strains. We define this as the paradox of PrEP (i.e., resistance appears to be increasing, but is actually decreasing). We determine this paradox is likely to occur if the efficacy of PrEP regimens against wild-type strains is greater than 30% and the relative efficacy against resistant strains is greater than 0.2 but less than the efficacy against wild-type. Our modeling shows, if risk behavior increases, that it is a valid concern that PrEP could significantly increase transmitted resistance. However, if risk behavior remains stable, we find the concern is unfounded and PrEP interventions are likely to decrease transmitted resistance.

[1]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[2]  Kenneth H Mayer,et al.  Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education , 2009, Journal of acquired immune deficiency syndromes.

[3]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[4]  M. Kalish,et al.  Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United States , 2008, Journal of Clinical Microbiology.

[5]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[6]  Robert J. Smith,et al.  Could disease-modifying HIV vaccines cause population-level perversity? , 2004, The Lancet. Infectious diseases.

[7]  Louis Tong,et al.  Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men , 2008 .

[8]  Michael Monsour,et al.  Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.

[9]  P. Cane.  Stability of transmitted drug-resistant HIV-1 species , 2005, Current opinion in infectious diseases.

[10]  E. Vittinghoff,et al.  Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men , 2008, Journal of acquired immune deficiency syndromes.

[11]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[12]  H. Jaffe,et al.  Pre-exposure prophylaxis for HIV infection: what if it works? , 2007, The Lancet.

[13]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[14]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor , 2005, Nature Medicine.

[15]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[16]  S. Pinkerton.  How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? , 2007, AIDS.

[17]  M. Hudgens,et al.  Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. , 2006, The Journal of infectious diseases.

[18]  Doug Taylor,et al.  Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.

[19]  J. Bryant,et al.  Non-occupational postexposure prophylaxis for HIV: a systematic review. , 2009, Health technology assessment.

[20]  M. Carrington,et al.  Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical Course , 2008, Journal of acquired immune deficiency syndromes.

[21]  S. Karim,et al.  Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges , 2009 .

[22]  P. Vernazza,et al.  High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. , 1998, The Journal of infectious diseases.

[23]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[24]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[25]  Mirjam Kretzschmar,et al.  Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men , 2004, AIDS.

[26]  D. Pillay,et al.  Long-Term Persistence of Primary Genotypic Resistance After HIV-1 Seroconversion , 2004, Journal of acquired immune deficiency syndromes.

[27]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[28]  J. Catania,et al.  Changes in prevalence of HIV infection and sexual risk behavior in men who have sex with men in San Francisco: 1997 2002. , 2007, American journal of public health.

[29]  W. Heneine,et al.  Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection , 2010, Science Translational Medicine.

[30]  D. Stram,et al.  Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. , 1997, American journal of epidemiology.

[31]  D. Richman,et al.  Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Kenneth A. Rose,et al.  Parameter sensitivities, monte carlo filtering, and model forecasting under uncertainty , 1991 .

[33]  N. Pedersen,et al.  Prophylactic and Therapeutic Benefits of Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) Administration to Newborn Macaques following Oral Inoculation with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA , 2000, Journal of Virology.

[34]  M. Chesney,et al.  Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection , 2007, AIDS.

[35]  S. Buchbinder,et al.  Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. , 2006, JAMA.

[36]  C. Verhofstede,et al.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. , 1999, AIDS.

[37]  M. Wainberg,et al.  Chemoprophylaxis of HIV infection: moving forward with caution. , 2006, The Journal of infectious diseases.

[38]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[39]  Erin N. Bodine,et al.  Evolutionary Dynamics of Complex Networks of HIV Drug-Resistant Strains: The Case of San Francisco , 2010, Science.